Programme:

4th Monday

15:00–15:30 Welcome and Registration

15.30-16.00 XV ApoRed Meeting Opening

16.00–17.00 Opening Conference: Manel Juan: "Project ARI: Driving CAR-T to fight cancer... and beyond"

17.00-19:00 Session I: Cell death in cancer. Chair: Mar Orzáez.

(15 + 5 min)

- 1. Laura Mondragón Martínez: Apaf-1 role in T cell lymphoma appearance
- 2. Iñaki Arretxe Garcia: Deciphering the role of perforin and granzymes in CART19-mediated elimination of CD19+ leukemic cells.
- 3. Sara Oltra Sanchis: GSDMB isoforms differentially control pyroptotic cell death and mitochondrial damage in cancer cells.
- 4. Raquel López Rosa: Synergistic Effects of BET Inhibitors and TMZ in Overcoming Resistance in Glioblastoma.
- 5. David Tébar García: Taming Cancer's Defenses: Targeting Anti-apoptotic Pathways to Overcome Chemotherapy Resistance in Refractory Cells.

Flash Talks (5 min):

- 6. María Pilar Corral Sancho: Toll-like receptor-2 and Xc- system as potential targets for multiple myeloma.
- 7. Sandra Franco Caspueñas: Apoptosis of chemotherapy-induced senescent Vestibular Schwannoma cells by navitoclax.

19.00-20:00 Wine of honour

5thTuesday

9:00–10:45 Session 2: Cell death and novel therapies. Chair: Isabel Marzo

(15 + 5 min)

- 1. Gaël Roué: Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma.
- 2. Andrea Benedí: Antitumor activity of novel selective Aurora kinase inhibitors alisertib and barasertib in multiple myeloma cell lines.
- 3. Mohammed Moustapha Anwar: The novel dihydrooratate dehydrogenase (DHODH) inbibitor UNL-1 triggers high levels of DNA damage damage in colorectal cancer cells.
- 4. Víctor Salido-Subiñas: Cathepsin D and B impact in the anti-tumor efficacy of CART-BCMA cells against Multiple Myeloma and in the neurotoxicity after CAR-T therapy.

Flash Talks (5 min):

- 5. Inés Méndez: Exploring a Novel Antioxidant Strategies with Nitrones for the Treatment of Sensorineural Hearing Loss.
- 6. Paula Sánchez Olivares: Targeting Triple-Negative Breast Cancer with a Curcumin-Based Mesoporous Silica Nanoparticle System.
- 7. Alejandro Pinedo Serrano: Searching new targets in refractory tumors using PROTACs.

10:45–11:15 Coffee break. Stands: MedChemexpress, Bionova, DeltaLab, HaploX.

11:15–13:00 Session 3: Novel forms of cell death. Chair: Federico Lucantoni

Invited speaker (30 min): Emir Bozkurt: Single-cell Spatial Analysis of Cell-in-Cell Structures in Colorectal Cancer.

(15 + 5 min)

- 1. Alejandro Failde Fiestras: The Last Kiss: Apoptotic Secreted Factors drive Apoptosis-Induced Senescence (AIS)
- 2. Federico Lucantoni: Activation of ROCK1 Increase the Occurrence of Entosis in Breast Cancer Cells.
- 3. Invited speaker: Joan Montero: Apoptotic protection in therapy-induced senescent melanoma cells is mediated through BCL-xL binding to BAK.
- 4. Iswarya Sreeram: Palbociclib induces pseudo-senescence in pleural mesothelioma cells, and does not sensitize the cells to combinations with classical senolytics.

13:00-14:00 Short commercial talks:

- Laura Fernandez. Condalab: Say goodbye to your cells with the best support!
- Elena López. Merck group: Milliplex Case Studies.

14:00–15:30 Lunch break. Stands: MedChemexpress, Bionova, DeltaLab, HaploX.

15:30–17:00 Session 4: Cell death and immunogenicity I. Chair: Beatriz Martín.

(15 + 5 min)

- 1. Sandra Hidalgo Arizón: NK cells induce death by necroptosis through TNF- α in susceptible cancer cells.
- 2. Mario Herrero-Cervera: Unravelling the role of an ER-localized AAA-ATPase, ATFRAT1, in plant immunogenic cell death.
- 3. Alejandro Andrés Tovar: Granzyme A in RNA viral infections

Flash talks (5 min):

- 4. Enric Dolz Andrés: Analysis of extracellular histone-associated cytotoxicity in a human cardiomyocyte model
- 5. Elena Nacher Sendra: How Do Extracellular Histones Affect a Kidney Cell Model and Contribute to Oxidative Stress? Exploring the Transition from 2D to 3D Cellular Models.

17:00-17:30 Coffee break. Stands: MedChemexpress, Bionova, DeltaLab, HaploX.

17:30–18:45 Session 5: Cell death and immunogenicity II. Chair: Laura Mondragón.

(15 + 5 min)

- 1. Juan Sastre: p53 causes necroptosis in acute pancreatitis through down-regulation of sulfiredoxin and peroxiredoxin 3.
- 2. Iván Fernández Pérez: Identification of a novel ASC-dependent inflammasome inhibitor.
- 3. Patricia Rodríguez Tascón: Cytotoxic effects of extracellular histones and HMGB1 on vascular cell models: implications for sepsis.

Flash talks (5 min):

4. Irene Cánovas-Cervera: The use of miRNA expression for the diagnosis and prediction of negative outcomes in sepsis.

18.45-20:00. General Assembly

6th Wednesday

9:00-11:00 Session 6: Cell death, metabolism and autophagy. Chair: Eva Galán Moya.

Invited speaker (30 min): Marina Garcia: Autophagy role in the brain-to-periphery axis.

(15 + 5 min)

- 1. Invited speaker: Hector Flores Romero: MTCH2 modulates apoptotic foci formation
- 2. Mabel Cruz Rodriguez: Glucose starvation induced cell death is regulated by the Unfolded Protein response in NSCLC
- Gema Hurtado-Genovés: LIGHT deficiency in Apoe-/- mice increases atheroma plaque by enhancing apoptosis

Flash Talks (5 min):

- 4. Ángela Berlana San Segundo: Evaluation of the effects of a c-Jun N-terminal kinase inhibitor on the progression of metabolic dysfunction-associated steatotic liver disease and associated hepatocellular lipotoxicity.
- 5. Juan Guerrero Mauvecín: The role of necroptosis in Aristolochic acid nephropathy (AAN).
- 11:00–11:30 Coffee break. Stands: MedChemexpress, Bionova, DeltaLab, HaploX.

11:30-12:30. Session 7: Non-canonical roles of cell death proteins. Chair: Joan Montero

(15 + 5 min)

- 1. Marta Salas-Gómez Deciphering the role of the Arabidopsis Metacaspase 1 in heat stress response.
- 2. Noelia Pastor-Cantizano: Programmed cell death regulator BAP2 is required for IRE1mediated unfolded protein response in Arabidopsis.
- 3. Joaquín Jordán Bueso. To be determined
- 12:30-13:30 Closing Conference: Triona Ni Chonghaile. Inducing BCL-2 reliance in Multiple Myeloma and sensitivity to venetoclax.
- 13:30-14:00 Concluding remarks.



















